The role of AI in clinical trials

With rapid increase in the use of artificial intelligence in healthcare, the need for thoughtful, ethical, and impactful application to support clinical trials is imperative. This webinar explored the current and future applications of artificial intelligence for clinical trial design, conduct, and reporting, with a focus on the ethical considerations of these new technologies.
Dr Danielle Bitterman is an Assistant Professor in the Department of Radiation Oncology at Brigham and Women’s Hospital/Dana-Farber Cancer Institute, Harvard Medical School. Dr. Bitterman is a physician-scientist whose expertise is in artificial intelligence and natural language processing. Her research is focused on improving data driven cancer care and her laboratory develops natural language processing methods that process high volumes of data from electronic health records to inform care and facilitate communication.
Dr. Subha Perni is an Assistant Professor in the Department of Radiation Oncology at MD Anderson Cancer Center. Dr. Perni specializes in the care of patients with central nervous system malignancies. Her research focuses on designing prospective patient-centered clinical trials incorporating advanced technology and imaging with the aim of improving quality of life and outcomes for these patients. She has additional expertise in ethics and decision-making.

[@Aldraz]

YT randomly recommended me this video, probably because I am developing an AI platform myself, but it is very interesting we can already use an AI in clinical trials. I think the problems you have mentioned are mostly details that will be fixed with a small improvement, like biases, hallucinations, etc.. but what we really need is for AIs to have actual reasoning skills, planning, executing, long-term thinking, etc.. those are some of the last missing pieces. After that we can do something much closer to real digital-twins. And with a perfect digital-twins you could probably skip the whole clinical trials as such and release the drug, quite literally to the public without waiting for years. But that is still a sci-fi for now.. and still might take about 2-5 years until we get to that point unfortunately. And then probably another 10 years until it is gonna be approved by the slow regulatory system lol.